Press Release Lorenzen Cancer Foundation Urges Cancer Drug Coverage in the Prescription Drug Benefit Act

In the interests of cancer patients and oncologists nationwide, the Lorenzen Cancer Foundation (LCF), a non-profit dedicated to fighting pancreatic cancer, has joined the public interest law firm Washington Legal Foundation (WLF) and others today in presenting a written comments statement to the U.S. Centers for Medicare and Medicaid Services (CMS) voicing support for the Section 641 demonstration project and expressing concerns regarding CMS’s proposed restrictions limiting coverage of the drug benefit to exclude off-label uses of FDA-approved drug or biological therapies.

Monterey, CA July 7, 2004 -- In the interests of cancer patients and oncologists nationwide, the Lorenzen Cancer Foundation (LCF), a non-profit dedicated to fighting pancreatic cancer, has joined the public interest law firm Washington Legal Foundation (WLF) and others today in presenting a written comments statement to the U.S. Centers for Medicare and Medicaid Services (CMS) voicing support for the Section 641 demonstration project and expressing concerns regarding CMS’s proposed restrictions limiting coverage of the drug benefit to exclude off-label uses of FDA-approved drug or biological therapies.

Once the Food and Drug Administration approves a drug for marketing, physicians may prescribe the drug for purposes other than those that the FDA has given specific indication. Off-label prescribing is common in cancer treatment as drugs often work well for many types of cancer. A General Accounting Office analysis in 1991 demonstrated that over half of cancer patients received at least one off-label medicine in the course of their care.

In enacting Section 641 of the Medicare Prescription Drug and Modernization Act of 2003, Congress did not exclude off-label uses from the demonstration project related to Section 641. To the contrary, Section 641(a) directs that the project be conducted following the standards of the part D benefit program which does not exclude off-label use.

Recently announced proposed eligibility criteria by the CMS effectively exclude the coverage of off-label use of FDA-approved agents for cancer therapy and in other serious diseases.
   
Today’s statement urges CMS officials to reverse this position and to make clear to the public and to medical providers that Medicare will reimburse for off-label use for medications and biological therapies in the demonstration project related to Section 641. And further, to make clear that any proposed or actual restriction on off-label use in the demonstration project is not a precedent for full enactment of the part D prescription drug benefit program.

Pancreatic Cancer Facts:
· Pancreatic cancer is the most virulent of the major cancers
· Pancreatic cancer research is the least funded of the major cancers
· Pancreatic cancer causes more than 1% of all death in the U.S.
· Pancreatic cancer is the fourth most common cause of cancer mortality

The Lorenzen Cancer Foundation is a 501(c)(3) non-profit organization dedicated to the fight against pancreatic cancer. LCF is oriented to increasing awareness and education about pancreatic cancer, helping physicians and patients create optimal treatment strategies, and fostering the development of a molecular or genetic marker to aid in diagnosis. For more information visit www.pancreatica.org

Media Contact:
Aaron Stoertz
Media Relations
Lorenzen Cancer Foundation
(831) 658-0600

Company Contact:
Ellen Pansky, esq.
Director of Public Policy
Lorenzen Cancer Foundation
(831) 658-0600

Latest Cancer News:

CBC.ca

Insight: Komen charity under microscope for funding, science Reuters By Sharon Begley and Janet Roberts | NEW YORK (Reuters) - The Susan G. Komen for the Cure charity defines its mission as finding a cure for breast cancer. In recent years, however, it has cut by nearly half the proportion of fund-raising dollars it ... Komen foundation shouldn't give any money to Planned ParenthoodBaltimore Sun Komen executive quits as questions persistLos Angeles Times Komen exec quits after Planned Parenthood flapFox News all 3,851 news articles »

Daily Mail

Breast cancer kills older women more often Fox News Print Email Share Comments Recommend Tweet Breast cancer is often considered more deadly among younger women, but a new study shows older women are actually more likely to die of the disease. Researchers found that among women who had been diagnosed ... Breast cancer kills older women more often: studyReuters Older women at breast cancer death riskTimes of India Breast cancer screening 'no longer justified' and causes 7000 women a year to ...Daily Mail ABC News -Tempo all 100 news articles »

Pa. woman gets probation for fake cancer claims USA TODAY (AP) ? A Pennsylvania woman who submitted nearly $100000 worth of fake cancer treatment insurance claims for herself and her husband must repay the money while she serves nearly nine years on probation. The Observer-Reporter of Washington, ... and more »

Forbes

Should We Stop Trying To Cure Cancer? Forbes But David Agus points out in his wonderful new book, The End of Illness (2012), that most of the effort and massive expenditure in combating the major adult diseases like cancer and heart disease are focused on trying to cure the disease. and more »

Author Brings Business 'Cancer' Relief and Guaranteed Growth for Ailing Companies MarketWatch (press release) Cancer-proof your company and see tremendous growth when you follow the guidelines of Wilson Worst in her book "Cut the Cancer From Your Company...and Increase Productivity 75%!" CHESAPEAKE, Va., Feb. 8, 2012 /PRNewswire via COMTEX/ -- What's hiding in ... and more »

NH hospital officials blast for-profit cancer center bill The Union Leader By TED SIEFER CONCORD ? Representatives of the state's major hospitals fought a proposal that could pave the way for a for-profit cancer facility to come to the state at a hearing Tuesday that was notable for the absence of the company that was the ... Cancer Center Bill Gets Chilly Reception at StatehousePatch.com NH considers bending rules for cancer centerBoston.com Does New Hampshire Need Specialty Cancer Centers?New Hampshire Public Radio Concord Monitor all 30 news articles »

USA TODAY

FDA Questions Benefit of Amgen Bone Drug in Certain Cases Wall Street Journal (blog) By Jennifer Corbett Dooren The Food and Drug Administration questioned the clinical benefit of using Amgen's bone drug Xgeva to prevent or delay the spread of prostate cancer to the bones. Xgeva is currently approved to delay fractures and other bone ... FDA questions Amgen drug for prostate cancerCBS News all 222 news articles »

RedOrbit

Breast cancer claims Purdue astronaut Janice Voss, 55 Journal and Courier Astronaut Janice E. Voss, a Purdue University graduate and one of the few women launched into space, died Monday in Scottsdale, Ariz., after a battle with breast cancer. She was 55. Voss was part of five space shuttle missions, spending a total of 49 ... Cancer Claims Five-Time Shuttle AstronautDiscovery News Janice Voss, Shuttle Astronaut, Dies of Cancer at 55ThirdAge NASA Astronaut Janice Voss Loses Battle Against Breast CancerRedOrbit WIFR -Boston.com all 189 news articles »

First in Print: SIU-Springfield, SIH to be part of cancer study Benton Evening News By Anonymous Southern Illinois University School of Medicine in Springfield, Southern Illinois Healthcare (SIH) Cancer Institute in Carbondale and the Illinois State Cancer Registry will collaborate on a two-year study that will explore disparities in ... Study to look at lung cancer in Southern IllinoisWJBC News all 17 news articles »

Cancer survivors get stronger at CTRC's new fitness facility San Antonio Express By Marvin Pfeiffer The new fitness center at the Cancer Therapy & Research Center at the University Health Science Center at San Antonio is up and running and off to a great start. Stacey Young-McCaughan, a registered nurse and a professor in the ... and more »